Highly Expressing SCARA5 Promotes Proliferation and Migration of Esophageal Squamous Cell Carcinoma
Table 4
Clinicopathological significances of SCARA5 expression in esophageal carcinoma patients.
Characteristics
SCARA5 expression
a
Higher (%)
Lower (%)
Specimen
55.4
<0.01
Adjacent normal tissue
80
13 (16.3)
67 (83.7)
ESCC
100
72 (72.0)
28 (28.0)
Sex
0.13
0.72
Male
74
54 (73.0)
20 (27.0)
Female
26
18 (69.2)
8 (30.8)
Age (y)
0.25
0.62
<68
54
40 (74.1)
14 (25.9)
≥68
46
32 (69.6)
14 (30.4)
Clinical stage
0.59
0.44
I-II
49
37 (75.5)
12 (24.5)
III
51
35 (68.6)
16 (31.4)
Tumor location
0.31
0.86
Upper
4
3 (75.0)
1 (25.0)
Middle
26
18 (69.2)
8 (30.8)
Lower
25
19 (76.0)
6 (24.0)
T classification
0.02
0.88
T1-2
17
13 (76.5)
4 (23.5)
T3-4
83
59 (71.1)
24 (28.9)
N classification
0.51
0.47
N0
45
34 (75.6)
11 (24.4)
N1-3
55
38 (69.1)
17 (30.9)
Differentiation
4.75
0.09
Well
6
6 (100.0)
0 (0.0)
Moderately
66
48 (72.7)
18 (27.3)
Poorly
28
18 (64.3)
10 (35.7)
Number of tumors
0.61
0.44
1
80
61 (76.3)
19 (23.8)
2
5
3 (60)
2 (40)
Longest diameter of tumor (cm)
0.04
0.85
<5
42
32 (76.2)
10 (23.8)
≥5
43
32 (74.4)
11 (25.6)
Tumor volume (cm3)
0.67
0.41
<22.5
43
34 (79.1)
9 (20.9)
≥22.5
42
30 (71.4)
12 (28.6)
Abbreviations: T: tumor; N: lymph node; clinical stage: according to the American Joint Committee on Cancer staging standard; tumor volume: .aBold type indicates statistical significance. Likelihood ratio.
